Gene therapy in rheumatoid polyarthritis: Perspectives;Therapie genique dans la polyarthrite rhumatoide: Perspectives

Presse Medicale

Volumn 27, Issue 12, 1998, Pages 580-582

  Bessis, N ^b   Boissier, M C ^a  

^a AVICENNE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; METALLOPROTEINASE INHIBITOR; INTERLEUKIN 1 RECEPTOR;

DNA TRANSFECTION; EXPRESSION VECTOR; GENE EXPRESSION; GENE INSERTION; GENE THERAPY; GENE TRANSFER; HUMAN; POLYARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; FEASIBILITY STUDY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; INJECTION; INTRAARTICULAR DRUG ADMINISTRATION; RISK ASSESSMENT;

ANIMALS; ARTHRITIS, RHEUMATOID; CYTOKINES; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INJECTIONS; INJECTIONS, INTRA-ARTICULAR; RECEPTORS, INTERLEUKIN-1; RISK ASSESSMENT; TRANSFECTION;

EID: 0032574391     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Elliott MJ, Maini RN, Feldmann M et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 ; 344:1105-10.
2. Smith KT, Sheperd AJ, Boyd JE, Lees GM. Gene delivery systems for use in gene therapy : an overview of quality assurance and safety issues. Gene Ther 1996 ; 3:190-200.
3. Boissier MC, Bessis N. Gene therapy in rheumatology. From laboratory to patient. Rev Rhum (Engl Ed) 1997 ; 64:1-3.
4. Boissier MC, Bessis N, Roth C, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis by interleukin-4 using gene therapy (abs). Arthritis Rheum 1993 ; 36:545.
5. Roessler BJ, Hartmann JW, Vallance DK, Latta JM, Janich SL, Davidson BL. Inhibition of interleukin-1 induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther 1995 ; 6:307-16.
6. Evans CH, Robbins PD, Ghivizzani SC et al. Clinical trial to assess safety, feasibility and efficacy of transfecrring o potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996 ; 7:1261-80.
7. Bessis N, Boissier MC, Ferrara P, Blankestein T, Fradelizi D, Fournier C. Attenuation of murine collagen-induced arthritis with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996 ; 26:2399-403.
8. Bessis N, Chiocchia G, Kollias G et al. Modulation of proinflammatory cytokine production by treatment with interleukin (IL)-4, IL-10 or IL-13 in TNF-α transgenic mice. Clin Exp Immunol 1998 ; 11:391-6.
9. Batteux F, Bessis N, Breban M, Boissier MC, Fournier C, Chiocchia G. Curative effect in murine collagen-induced arthritis of CHO cells co-transfected with IL-4 and Fas ligand genes (abs). Immunology Letters 1997 ; 56:372.
10. Zhang H, Yang Y, Horton JL et al. Amelioration of collagen-induced arthritis by CD-95 (Apo-l/Fas)-ligand gene transfer. J Clin Invest 1997 ; 100:1951-7.
11. Bessis N, Honiger J, Caput D, Fradelizi D, Fournier C, Boissier MC. Use of hollow fibers filled with cells engineered to secrete IL-4 or IL-13 for treatment of experimental arthritis (abs). Arthritis Rheum 1996 ; 39:S308.